The Chicago-based Tempus spinout called the financing round a major milestone as it expands its AI-enabled platform.

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has ...

Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest ...

FDA Commissioner Marty Makary said Thursday that his agency is preparing to release a new regulatory framework within the ...

CEO Önal said Türk Telekom had a ‘spectacular’ start to the year, primarily driven by the maintained strength in fixed ...

Tezepelumab demonstrated rapid and sustained clinical improvements in nasal polyp burden and symptom control, with effects ...